The Role of the Woodchuck Model in the Treatment of Hepatitis B Virus Infection

Clinics in Liver Disease

Volumn 11, Issue 4, 2007, Pages 707-725

  Kulkarni, Ketan ^a   Jacobson, Ira M ^a   Tennant, Bud C ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Animal Health Diagnostic Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CLEVUDINE; COMPLEMENTARY DNA; CYCLOSPORIN A; DOUBLE STRANDED DNA; ENTECAVIR; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PLACEBO; VIRUS DNA; VIRUS RNA;

ANTIBIOTIC RESISTANCE; CANCER GROWTH; CHEMOPROPHYLAXIS; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL RESEARCH; MOLECULAR CLONING; NONHUMAN; REVIEW; RISK FACTOR; SEROLOGY; TREATMENT OUTCOME; VIRUS CARRIER; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS, WOODCHUCK; HUMANS; LIVER NEOPLASMS; MARMOTA;

EID: 35548960369     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.08.012     Document Type: Review

References (84)

1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet No. 204. Available at: http://who.int/mediacentre/factsheets/fs204/en. Accessed March 1, 2007.
2. Levanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
3. Lai C.L., Ratziu V., Yuen M.F., et al. Viral hepatitis B. Lancet 362 (2003) 2089-2094
4. Tennant B.C., and Gerin J.L. The woodchuck model of hepatitis B virus infection. ILAR J 42 2 (2001) 89-102
5. Tennant B.C., Toshkov I.A., Peek S.F., et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127 (2004) S283-S293
6. Menne S., and Cote P.J. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 13 1 (2007) 104-124
7. Menne S., and Tennant B.C. Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). Nat Med 5 10 (1999) 1125-1126
8. Summers J., Smolec J.M., and Snyder R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA 75 (1978) 4533-4537
9. Tyler G.V., Summers J.W., and Snyder R.L. Woodchuck hepatitis virus in natural woodchuck populations. J Wildl Dis 17 2 (1981) 297-301
10. Galibert F., Chen T.N., and Mandart E. Nucleotide sequence of a cloned woodchuck hepatitis virus sequence. J Virol 41 (1982) 51-65
11. Marion P.L., Oshiro L.S., Regnery D.C., et al. A virus in Beechey ground squirrels that is related to hepatitis B virus in humans. Proc Natl Acad Sci USA 77 5 (1980) 2941-2945
12. Marion P.L., Van Davelaar M.J., Knight S.S., et al. Hepatocellular carcinoma in ground squirrels persistently infected with ground squirrel hepatitis virus. Proc Natl Acad Sci USA 83 12 (1986) 4543-4546
13. Funk A., Mhamdi M., Will H., et al. Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism. World J Gastroenterol 13 1 (2007) 91-103
14. Lee W. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
15. McMahon B.J., Alward W.L.M., Hall D.B., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 151 (1985) 599-603
16. Keeffe E.B., Dieterich D.T., Han S.B., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 8 (2006) 936-961
17. Di Bisceglie A.M., Waggoner J.G., and Hoofnagle J.H. Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers: correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy. Gastroenterology 93 (1987) 1236-1241
18. Lok A.S.F., and McMahon B.J. AASLD practice guidelines: chronic hepatitis B. Hepatology 45 2 (2007) 507-539
19. Tennant B.C. Animal models of hepadnavirus-associated hepatocellular carcinoma. Clin Liver Dis 5 (2001) 43-68
20. Popper H., Roth L., Purcell R.H., et al. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci USA 84 (1987) 866-870
21. Popper H., Shafritz D.A., and Hoofnagle J.H. Relation of the hepatitis B virus carrier state to hepatocellular carcinoma. Hepatology 7 4 (1987) 764-772
22. Yang H.I., Lu S.N., Liaw Y.F., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
23. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 296 (2006) 65-73
24. Lupberger J., and Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 13 1 (2007) 74-81
25. Kaneko S., Oshima T., Kodama K., et al. Stable integration of woodchuck hepatitis virus DNA in transplanted tumors and established tissue culture cells derived from a woodchuck primary hepatocellular carcinoma. Cancer Res 46 (1986) 3608-3613
26. Korba B.E., Wells F.V., Baldwin B., et al. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 9 3 (1989) 461-470
27. Fuchs K., Heberger C., Weimer T., et al. Characterization of woodchuck hepatitis virus DNA and mRNA in the hepatocellular carcinomas of woodchucks. Hepatology 10 2 (1989) 215-220
28. Schildiner O., and Benvenisty N. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene 20 36 (2001) 4984-4994
29. Wei Y., Fourel G., Ponzetto A., et al. Hepadnavirus integration: mechanisms of activation of the N-myc2 retrotransposon in woodchuck liver tumors. J Virol 66 9 (1992) 5265-5276
30. Fourel G., Trepo C., Bougueleret L., et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumors. Nature 347 (1990) 294-298
31. Flajolet M., Tiollais P., Buendia M.-A., et al. Woodchuck hepatitis virus enhancer I and enhancer II are both involved in N-myc2 activation in woodchuck liver tumors. J Virol 72 7 (1998) 6175-6180
32. Renard C.A., Fourel G., Bralet M.P., et al. Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles. Oncogene 19 22 (2000) 2678-2686
33. Transy C., Fourel G., Robinson W.S., et al. Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. Proc Natl Acad Sci USA 89 9 (1992) 3874-3878
34. Seeger C., Baldwin B., Hornbuckle W.E., et al. Wooodchuck hepatitis virus is a more efficient oncogenic agent than ground squirrel hepatitis virus in a common host. J Virol 65 4 (1991) 1673-1679
35. Jacob J.R., Sterczer A., Toshkov I.A., et al. Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors. Hepatology 39 (2004) 1008-1016
36. Yang D., Alt E., and Rogler C.E. Coordinate expression of N-myc2 and insulin-like growth factor II in precancerous altered hepatic foci in woodchuck hepatitis virus carriers. Cancer Res 53 9 (1993) 2020-2027
37. Su Q., Benner A., Hofmann W.J., et al. Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch 431 (1997) 391-406
38. Su Q., and Bannasch P. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol Pathol 31 1 (2003) 126-133
39. Bannasch P., Haertel T., and Su Q. Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol Pathol 31 1 (2003) 134-139
40. Shafritz D.A., Shouval D., Sherman H.I., et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsy and post-mortem tissue specimens. N Engl J Med 305 18 (1981) 1067-1073
41. Murakami Y., Saigo K., Takashima H., et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54 8 (2005) 1162-1168
42. Tokino T., Fukushige S., Nakamura T., et al. Chromosomal translocation and inverted duplication associated with integrated hepatitis B virus in hepatocellular carcinomas. J Virol 61 (1987) 3848-3854
43. Ferber M.J., Montoya D.P., Yu C., et al. Integration of hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase gene in lever and cervical cancers. Oncogene 22 (2003) 3813-3820
44. Brechot C., Gozuacik D., Murakami T., et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 10 (2000) 211-231
45. Bruni R., Conti I., Villano U., et al. Lack of WHV integration nearby N-myc2 and in the downstream, b3n and win loci in a considerable fraction of liver tumors with activated N-myc2 from naturally infected wild woodchucks. Virology 345 1 (2006) 258-269
46. Chen W.N., and Oon C.J. Hepatitis B virus mutants: an overview. J Gastroenterol Hepatol 17 (2002) S497-S499
47. Korba B.E., Cote P., Hornbuckle W., et al. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31 5 (2000) 1165-1175
48. Hurwitz S.J., Tennant B.C., Korba B.E., et al. Pharmacodynamics of (-)-beta-2′,3′-dideoxy-3′-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans. Antimicrob Agents Chemother 42 11 (1998) 2804-2809
49. Hurwitz S.J., Tennant B.C., Korba B.E., et al. Viral pharmacodynamic model for beta-2′,3′-dideoxy-3′-5-fluoro-3′-thiacytidine (emtricitabine) in chronically infected woodchucks. Antivir Chem Chemother 13 (2002) 165-176
50. Menne S., Cote P.J., Korba B.E., et al. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 49 7 (2005) 2720-2728
51. Korba B.E., Cote P., Hornbuckle W., et al. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antiviral Res 45 1 (2000) 19-32
52. Cullen J.M., Li D.H., Brown C., et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 45 (2001) 2740-2745
53. Standring D.N., Bridges E.G., Placidi L., et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 12 S1 (2001) 119-129
54. Bryant M.L., Bridges E.G., Placidi L., et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 45 (2001) 229-235
55. Peek S.F., Cote P.J., Jacob J.R., et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33 (2001) 254-266
56. Le Mire M.F., Miller D.S., Foster W.K., et al. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection. J Virol 79 19 (2005) 12242-12252
57. Yoo B.C., Kim J.H., Chung Y.H., et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 45 (2007) 1172-1178
58. Liaw Y.F., Sung J.J.Y., Chow W.C., et al. Cirrhosis Asian Lamivudine Multicenter Study Group: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
59. Peek S.F., Toshkov I.A., Erb H.N., et al. 3′-Thiacytidine (3TC) delays development of hepatocellular carcinoma (HCC) in woodchucks with experimentally induced chronic woodchuck hepatitis virus (WHV) infection: preliminary results of a lifetime study. [abstract]. Hepatology 26 (1997) 368A
60. Colonno R.J., Genovesi E.V., Medina I., et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 184 (2001) 1236-1245
61. Mason W.S., Cullen J., Moraleda G., et al. Lamivudine therapy of WHV-infected woodchucks. Virology 245 (1998) 18-32
62. Liaw Y.F., Leung N.W.Y., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 199 (2000) 172-180
63. Zhou T., Saputelli J., Aldrich C.E., et al. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 43 8 (1999) 1947-1954
64. Tatti K.M., Korba B.E., Stang H.L., et al. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antiviral Res 55 (2002) 141-150
65. Jacob J.R., Korba B.E., Cote P.J., et al. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res 63 (2004) 115-121
66. Korba B.E., Cote P., Hornbuckle W., et al. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks. Antivir Ther 5 (2000) 95-104
67. Santantonio T., Niro G.A., Sinisi E., et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 36 6 (2002) 799-804
68. Economou M., Manolakopoulous S., Trikalinos T.A., et al. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 11 37 (2005) 5882-5887
69. Nikolaidis N.L., Giouleme O.I., Tziomalos K.A., et al. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients. J Gastroenterol Hepatol 20 11 (2005) 1721-1725
70. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alpha-2a, lamivudine, and the combination for HbeAg-positive chronic hepatitis B. N Engl J Med 352 26 (2005) 2682-2695
71. Foster W.K., Miller D.S., Scougall C.A., et al. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection. J Virol 79 9 (2005) 5819-5832
72. Lu M., Klaes R., Menne S., et al. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens. J Hepatol 39 (2003) 405-413
73. Menne S., Roneker C.A., Korba B.E., et al. Immunization with surface antigen vaccine alone and after treatment wit 1-(2-Fluoro-5-Methyl-B-L_Arabinofuranosy)-Uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 76 11 (2002) 5305-5314
74. Korba B.E., Cote P.J., Menne S., et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 9 (2004) 937-952
75. Menne S., Roneker C.A., Tennant B.C., et al. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 45 (2002) 237-250
76. Lisi D., Kondili L.A., Ramieri M.T., et al. Ultrasonography in the study of hepatocellular carcinoma in woodchucks chronically infected with WHV. Lab Anim 37 3 (2003) 233-240
77. Nada T., Moriyasu F., Kono Y., et al. Sonographic depiction of woodchuck hepatomas using intravenously injected contrast agents. Nippon Rinsho 56 4 (1998) 980-984
78. McKenzie E.J., Jackson M., Turner A., et al. Chronic care and monitoring of woodchucks during repeated magnetic resonance imaging of the liver. J Am Assoc Lab Anim Sci 45 2 (2006) 26-30
79. Salem N., Maclennan G.T., Kuang Y., et al. Quantitative evaluation of 2-deoxy-2[f-18]fluoro-D:-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histologic correlation. Mol Imaging Biol 9 3 (2007) 135-143
80. Dahmen U., Li J., Dirsch O., et al. A new model of hepatitis B virus reinfection: liver transplantation in the woodchuck. Transplantation 74 3 (2002) 373-380
81. Dahmen U., Dirsch O., Li J., et al. Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 77 7 (2004) 965-972
82. Wang F., Anderson P.W., Salem N., et al. Gene expression studies of hepatitis virus-induced woodchuck hepatocellular carcinoma in correlation with human results. Int J Oncol 30 1 (2007) 33-44
83. Summers J., and Mason W.S. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 101 2 (2004) 638-640
84. Menne S., Cote P.J., Butler S.D., et al. Immunosupression reactivates viral replication long after resolution of woodchuck hepatitis virus infection. Hepatology 45 3 (2007) 614-622